CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-05 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −2,174 | $46.65 | $101K | 107,287 |
| 2026-05-04 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +4,250 | 121,149 | ||
| 2026-05-04 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Grant or award · Performance-based restricted stock units 10b5-1 | +8,500 | 8,500 | ||
| 2026-05-04 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Option exercise · Performance-based restricted stock units 10b5-1 | −4,250 | 4,250 | ||
| 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +20,000 | $22.40 | $448K | 131,473 |
| 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −20,000 | $45.00 | $900K | 111,473 |
| 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +4,250 | 115,723 | ||
| 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −20,000 | 34,500 | ||
| 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | Grant or award · Performance-based restricted stock units 10b5-1 | +8,500 | 8,500 | ||
| 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | Option exercise · Performance-based restricted stock units 10b5-1 | −4,250 | 4,250 | ||
| 2026-05-04 | Heerma Peter CHIEF COMMERCIAL OFFICER | Option exercise | +4,250 | 142,858 | ||
| 2026-05-04 | Heerma Peter CHIEF COMMERCIAL OFFICER | Grant or award · Performance-based restricted stock units | +8,500 | 8,500 | ||
| 2026-05-04 | Heerma Peter CHIEF COMMERCIAL OFFICER | Option exercise · Performance-based restricted stock units | −4,250 | 4,250 | ||
| 2026-05-04 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +22,500 | 455,386 | ||
| 2026-05-04 | Dube Eric M CHIEF EXECUTIVE OFFICER | Grant or award · Performance-based restricted stock units 10b5-1 | +45,000 | 45,000 | ||
| 2026-05-04 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Performance-based restricted stock units 10b5-1 | −22,500 | 22,500 | ||
| 2026-05-04 | ROTE WILLIAM E. Chief Research Officer | Option exercise 10b5-1 | +4,250 | 118,237 | ||
| 2026-05-04 | ROTE WILLIAM E. Chief Research Officer | Grant or award · Performance-based restricted stock units 10b5-1 | +8,500 | 8,500 | ||
| 2026-05-04 | ROTE WILLIAM E. Chief Research Officer | Option exercise · Performance-based restricted stock units 10b5-1 | −4,250 | 4,250 | ||
| 2026-05-04 | Meckler Jeffrey A Director | Option exercise 10b5-1 | +8,000 | $16.33 | $131K | 95,500 |
Page 8 of 41 · 802 trades